Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple Sclerosis

Multiple sclerosis (MS) is a severe debilitating disorder characterized by progressive demyelination and axonal damage of the central nervous system (CNS). Current therapies for MS inhibit the immune response and demonstrate reasonable benefits if applied during the early phase of relapsing–remittin...

Full description

Bibliographic Details
Main Authors: Marién Cobo, Per Anderson, Karim Benabdellah, Miguel G. Toscano, Pilar Muñoz, Angélica García-Pérez, Iván Gutierrez, Mario Delgado, Francisco Martin
Format: Article
Language:English
Published: SAGE Publishing 2013-05-01
Series:Cell Transplantation
Online Access:https://doi.org/10.3727/096368912X657404
id doaj-044fbe41ee4e48f0a14b020ec105d849
record_format Article
spelling doaj-044fbe41ee4e48f0a14b020ec105d8492020-11-25T02:22:15ZengSAGE PublishingCell Transplantation0963-68971555-38922013-05-012210.3727/096368912X657404Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple SclerosisMarién Cobo0Per Anderson1Karim Benabdellah2Miguel G. Toscano3Pilar Muñoz4Angélica García-Pérez5Iván Gutierrez6Mario Delgado7Francisco Martin8GENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, Parque Tecnológico Salud (PTS), Granada, SpainGENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, Parque Tecnológico Salud (PTS), Granada, SpainGENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, Parque Tecnológico Salud (PTS), Granada, SpainGENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, Parque Tecnológico Salud (PTS), Granada, SpainGENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, Parque Tecnológico Salud (PTS), Granada, SpainGENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, Parque Tecnológico Salud (PTS), Granada, SpainBiobanco, Parque Tecnológico Salud (PTS), Armilla, Universidad de Granada, Granada, SpainIPB Lopez Neyra, CSIC, Parque Tecnológico Salud (PTS), Armilla, Granada, SpainGENYO, Centre for Genomics and Oncological Research, Pfizer-University of Granada-Andalusian Regional Government, Parque Tecnológico Salud (PTS), Granada, SpainMultiple sclerosis (MS) is a severe debilitating disorder characterized by progressive demyelination and axonal damage of the central nervous system (CNS). Current therapies for MS inhibit the immune response and demonstrate reasonable benefits if applied during the early phase of relapsing–remitting MS (RRMS) while there are no treatments for patients that progress neither to the chronic phase nor for the primary progressive form of the disease. In this manuscript, we have studied the therapeutic efficacy of a cell and gene therapy strategy for the treatment of a mouse model of chronic MS [myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE)]. We used allogenic mesenchymal stem cells (MSCs) as a therapeutic tool and also as vehicle to deliver fully processed 3.3-kDa vasoactive intestinal peptide (VIP) to the peripheral immune organs and to the inflamed CNS. Intraperitoneal administrations of MSCs expressing VIP stopped progression and reduced symptoms when administered at peak of disease. The improvement in clinical score correlated with diminished peripheral T-cell responses against MOG as well as lower inflammation, lower demyelination, and higher neuronal integrity in the CNS. Interestingly, neither lentiviral vectors expressing VIP nor unmodified MSCs were therapeutic when administer at the peak of disease. The increased therapeutic effect of MSCs expressing VIP over unmodified MSCs requires the immunoregulatory and neuroprotective roles of both VIP and MSCs and the ability of the MSCs to migrate to peripheral lymph organs and the inflamed CNS.https://doi.org/10.3727/096368912X657404
collection DOAJ
language English
format Article
sources DOAJ
author Marién Cobo
Per Anderson
Karim Benabdellah
Miguel G. Toscano
Pilar Muñoz
Angélica García-Pérez
Iván Gutierrez
Mario Delgado
Francisco Martin
spellingShingle Marién Cobo
Per Anderson
Karim Benabdellah
Miguel G. Toscano
Pilar Muñoz
Angélica García-Pérez
Iván Gutierrez
Mario Delgado
Francisco Martin
Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple Sclerosis
Cell Transplantation
author_facet Marién Cobo
Per Anderson
Karim Benabdellah
Miguel G. Toscano
Pilar Muñoz
Angélica García-Pérez
Iván Gutierrez
Mario Delgado
Francisco Martin
author_sort Marién Cobo
title Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple Sclerosis
title_short Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple Sclerosis
title_full Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple Sclerosis
title_fullStr Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple Sclerosis
title_full_unstemmed Mesenchymal Stem Cells Expressing Vasoactive Intestinal Peptide Ameliorate Symptoms in a Model of Chronic Multiple Sclerosis
title_sort mesenchymal stem cells expressing vasoactive intestinal peptide ameliorate symptoms in a model of chronic multiple sclerosis
publisher SAGE Publishing
series Cell Transplantation
issn 0963-6897
1555-3892
publishDate 2013-05-01
description Multiple sclerosis (MS) is a severe debilitating disorder characterized by progressive demyelination and axonal damage of the central nervous system (CNS). Current therapies for MS inhibit the immune response and demonstrate reasonable benefits if applied during the early phase of relapsing–remitting MS (RRMS) while there are no treatments for patients that progress neither to the chronic phase nor for the primary progressive form of the disease. In this manuscript, we have studied the therapeutic efficacy of a cell and gene therapy strategy for the treatment of a mouse model of chronic MS [myelin oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis (EAE)]. We used allogenic mesenchymal stem cells (MSCs) as a therapeutic tool and also as vehicle to deliver fully processed 3.3-kDa vasoactive intestinal peptide (VIP) to the peripheral immune organs and to the inflamed CNS. Intraperitoneal administrations of MSCs expressing VIP stopped progression and reduced symptoms when administered at peak of disease. The improvement in clinical score correlated with diminished peripheral T-cell responses against MOG as well as lower inflammation, lower demyelination, and higher neuronal integrity in the CNS. Interestingly, neither lentiviral vectors expressing VIP nor unmodified MSCs were therapeutic when administer at the peak of disease. The increased therapeutic effect of MSCs expressing VIP over unmodified MSCs requires the immunoregulatory and neuroprotective roles of both VIP and MSCs and the ability of the MSCs to migrate to peripheral lymph organs and the inflamed CNS.
url https://doi.org/10.3727/096368912X657404
work_keys_str_mv AT mariencobo mesenchymalstemcellsexpressingvasoactiveintestinalpeptideamelioratesymptomsinamodelofchronicmultiplesclerosis
AT peranderson mesenchymalstemcellsexpressingvasoactiveintestinalpeptideamelioratesymptomsinamodelofchronicmultiplesclerosis
AT karimbenabdellah mesenchymalstemcellsexpressingvasoactiveintestinalpeptideamelioratesymptomsinamodelofchronicmultiplesclerosis
AT miguelgtoscano mesenchymalstemcellsexpressingvasoactiveintestinalpeptideamelioratesymptomsinamodelofchronicmultiplesclerosis
AT pilarmunoz mesenchymalstemcellsexpressingvasoactiveintestinalpeptideamelioratesymptomsinamodelofchronicmultiplesclerosis
AT angelicagarciaperez mesenchymalstemcellsexpressingvasoactiveintestinalpeptideamelioratesymptomsinamodelofchronicmultiplesclerosis
AT ivangutierrez mesenchymalstemcellsexpressingvasoactiveintestinalpeptideamelioratesymptomsinamodelofchronicmultiplesclerosis
AT mariodelgado mesenchymalstemcellsexpressingvasoactiveintestinalpeptideamelioratesymptomsinamodelofchronicmultiplesclerosis
AT franciscomartin mesenchymalstemcellsexpressingvasoactiveintestinalpeptideamelioratesymptomsinamodelofchronicmultiplesclerosis
_version_ 1724862413127286784